AIM: To explore the association between AT-rich interactive domain 1A (ARID1A) protein loss by immunohistochemistry and both clinicopathologic characteristics and prognosis in patients with colorectal cancer. METHODS: We retrospectively collected clinicopathologic data and archived paraffin-embedded primary colorectal cancer samples from 209 patients, including 111 patients with colon cancer and 98 patients with rectal cancer. The tumor stage ranged from stage I to stage IV according to the 7(th) edition of the American Joint Committee on Cancer tumor-node-metastasis (TNM) staging system. All patients underwent resection of primary colorectal tumors. The expression of ARID1A protein in primary colorectal cancer tissues was examined by immunohistochemical staining. The clinicopathologic association and survival relevance of ARID1A protein loss in colorectal cancer were analyzed. RESULTS: ARID1A loss by immunohistochemistry was not rare in primary colorectal cancer tumors (25.8%). There were 7.4%, 24.1%, 22.2% and 46.3% of patients with ARID1A loss staged at TNM stage I, II, III and IV, respectively, compared with 20.0%, 22.6%, 27.7% and 29.7% of patients without ARID1A loss staged at TNM stage I, II, III and IV, respectively. In patients with ARID1A loss, the distant metastasis rate was 46.3%. However, only 29.7% of patients without ARID1A loss were found to have distant metastasis. In terms of pathologic differentiation, there were 25.9%, 66.7% and 7.4% with poorly, moderately and well differentiated tumors in patients with ARID1A loss, and 14.2%, 72.3% and 13.5% with poorly, moderately and well differentiated tumors in patients without ARID1A loss, respectively. ARID1A loss was associated with late TNM stage (P = 0.020), distant metastasis (P = 0.026), and poor pathological classification (P = 0.035). However, patients with positive ARID1A had worse overall survival compared to those with negative ARID1A in stage IV colorectal cancer (HR = 2.49, 95%CI: 1.13-5.51). CONCLUSION: ARID1A protein loss is associated with clinicopathologic characteristics in colorectal cancer patients and with survival in stage IV patients.
AIM: To explore the association between AT-rich interactive domain 1A (ARID1A) protein loss by immunohistochemistry and both clinicopathologic characteristics and prognosis in patients with colorectal cancer. METHODS: We retrospectively collected clinicopathologic data and archived paraffin-embedded primary colorectal cancer samples from 209 patients, including 111 patients with colon cancer and 98 patients with rectal cancer. The tumor stage ranged from stage I to stage IV according to the 7(th) edition of the American Joint Committee on Cancer tumor-node-metastasis (TNM) staging system. All patients underwent resection of primary colorectal tumors. The expression of ARID1A protein in primary colorectal cancer tissues was examined by immunohistochemical staining. The clinicopathologic association and survival relevance of ARID1A protein loss in colorectal cancer were analyzed. RESULTS:ARID1A loss by immunohistochemistry was not rare in primary colorectal cancer tumors (25.8%). There were 7.4%, 24.1%, 22.2% and 46.3% of patients with ARID1A loss staged at TNM stage I, II, III and IV, respectively, compared with 20.0%, 22.6%, 27.7% and 29.7% of patients without ARID1A loss staged at TNM stage I, II, III and IV, respectively. In patients with ARID1A loss, the distant metastasis rate was 46.3%. However, only 29.7% of patients without ARID1A loss were found to have distant metastasis. In terms of pathologic differentiation, there were 25.9%, 66.7% and 7.4% with poorly, moderately and well differentiated tumors in patients with ARID1A loss, and 14.2%, 72.3% and 13.5% with poorly, moderately and well differentiated tumors in patients without ARID1A loss, respectively. ARID1A loss was associated with late TNM stage (P = 0.020), distant metastasis (P = 0.026), and poor pathological classification (P = 0.035). However, patients with positive ARID1A had worse overall survival compared to those with negative ARID1A in stage IV colorectal cancer (HR = 2.49, 95%CI: 1.13-5.51). CONCLUSION:ARID1A protein loss is associated with clinicopathologic characteristics in colorectal cancerpatients and with survival in stage IV patients.
Authors: A K Wong; F Shanahan; Y Chen; L Lian; P Ha; K Hendricks; S Ghaffari; D Iliev; B Penn; A M Woodland; R Smith; G Salada; A Carillo; K Laity; J Gupte; B Swedlund; S V Tavtigian; D H Teng; E Lees Journal: Cancer Res Date: 2000-11-01 Impact factor: 12.701
Authors: Norman G Nagl; Antonia Patsialou; Dale S Haines; Peter B Dallas; George R Beck; Elizabeth Moran Journal: Cancer Res Date: 2005-10-15 Impact factor: 12.701
Authors: Xiaomei Wang; Norman G Nagl; Deborah Wilsker; Michael Van Scoy; Stephen Pacchione; Peter Yaciuk; Peter B Dallas; Elizabeth Moran Journal: Biochem J Date: 2004-10-15 Impact factor: 3.857
Authors: J Jen; H Kim; S Piantadosi; Z F Liu; R C Levitt; P Sistonen; K W Kinzler; B Vogelstein; S R Hamilton Journal: N Engl J Med Date: 1994-07-28 Impact factor: 91.245
Authors: I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre Journal: Nature Date: 1998-07-09 Impact factor: 49.962
Authors: Lik Hang Lee; Eran Sadot; Sinisa Ivelja; Efsevia Vakiani; Jaclyn F Hechtman; Christopher J Sevinsky; David S Klimstra; Fiona Ginty; Jinru Shia Journal: Hum Pathol Date: 2016-03-02 Impact factor: 3.466
Authors: Ryan C Broderick; Arielle M Lee; Rachel R Blitzer; Beiqun Zhao; Jenny Lam; Joslin N Cheverie; Bryan J Sandler; Garth R Jacobsen; Mark W Onaitis; Kaitlyn J Kelly; Michael Bouvet; Santiago Horgan Journal: Surg Endosc Date: 2020-09-17 Impact factor: 4.584
Authors: Amir Mehrvarz Sarshekeh; Jumanah Alshenaifi; Jason Roszik; Ganiraju C Manyam; Shailesh M Advani; Riham Katkhuda; Anuj Verma; Michael Lam; Jason Willis; John Paul Shen; Jeffrey Morris; Jennifer S Davis; Jonathan M Loree; Hey Min Lee; Jaffer A Ajani; Dipen M Maru; Michael J Overman; Scott Kopetz Journal: Clin Cancer Res Date: 2021-01-07 Impact factor: 13.801
Authors: Claudio Luchini; Nicola Veronese; Marco Solmi; Hanbyoul Cho; Jae-Hoon Kim; Angela Chou; Anthony J Gill; Sheila F Faraj; Alcides Chaux; George J Netto; Kentaro Nakayama; Satoru Kyo; Soo Young Lee; Duck-Woo Kim; George M Yousef; Andreas Scorilas; Gregg S Nelson; Martin Köbel; Steve E Kalloger; David F Schaeffer; Hai-Bo Yan; Feng Liu; Yoshihito Yokoyama; Xianyu Zhang; Da Pang; Zsuzsanna Lichner; Giuseppe Sergi; Enzo Manzato; Paola Capelli; Laura D Wood; Aldo Scarpa; Christoph U Correll Journal: Oncotarget Date: 2015-11-17
Authors: Elena Fountzilas; Vassiliki Kotoula; Ioannis Tikas; Kyriaki Manousou; Kyriaki Papadopoulou; Christos Poulios; Vasilios Karavasilis; Ioannis Efstratiou; Dimitrios Pectasides; Kleo Papaparaskeva; Ioannis Varthalitis; Christos Christodoulou; George Papatsibas; Sofia Chrisafi; Georgios K Glantzounis; Amanda Psyrri; Gerasimos Aravantinos; Georgia-Angeliki Koliou; George K Koukoulis; George E Pentheroudakis; George Fountzilas Journal: Oncotarget Date: 2018-11-02